Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Disc Medicine, Inc. has initiated an underwritten offering of $200 million in common stock, with an additional option for underwriters to purchase up to$30 million more, aimed at funding research and clinical development for hematologic diseases [1][2]. Group 1: Offering Details - The offering consists of $200 million in common stock and pre-funded warrants for certain investors [1]. - Underwriters have a 30-day option to purchase an additional$30 million in shares at the public offering price [1]. - The offering is subject to market conditions and there is no assurance regarding its completion or terms [1]. Group 2: Use of Proceeds - Net proceeds from the offering will be used for research and clinical development of product candidates, including bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) [2]. - Funds will also support working capital and other general corporate purposes [2]. Group 3: Company Overview - Disc Medicine is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases [5]. - The company aims to create innovative therapeutic candidates targeting red blood cell biology, specifically heme biosynthesis and iron homeostasis [5].